# The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients

## TL;DR

This study shows that pangenotypic DAA treatments for hepatitis C significantly raise LDL and TC levels but do not affect insulin resistance.

## Contribution

The study compares the metabolic effects of two pangenotypic DAA regimens in chronic HCV patients.

## Key findings

- Both GLE/PIB and SOF/VEL regimens significantly increased LDL and TC levels after treatment.
- No significant changes were observed in triglycerides, HDL, HbA1C, or insulin resistance.
- Baseline LDL/TC and glucose levels predict the degree of lipid increase after treatment.

## Abstract

Hepatitis C virus (HCV) eradication is usually associated with dyslipidemia. Most studies in this field have focused on genotype-specific direct-acting antivirals (DAAs), with research on pangenotypic DAAs being limited. This study examined how two pangenotypic DAA regimens, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvir (SOF/VEL), affect lipid profiles and insulin resistance after viral eradication in chronic HCV patients. A total of 100 patients (57 with GLE/PIB and 43 with SOF/VEL) treated between September 2020 and January 2022 were included in the retrospective analysis. This study found a significant increase in LDL and TC levels after treatment (p < 0.001), but no significant changes in triglycerides, high-density lipoprotein, HbA1C, or the Homeostatic Model Assessment of Insulin Resistance. According to a logistic regression analysis, higher baseline LDL or TC and lower baseline glucose are predictors of the degree of increase in LDL or TC following a sustained virological response. Both pangenotypic DAA regimens significantly impact lipid profiles, particularly LDL and TC, but not insulin resistance. This study emphasizes the need for more research into the long-term metabolic effects of DAAs.